The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The optimal treatment (Tx) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) remains to be determined. Methods: A retrospective review was conducted on 77 NSCLC patients with synchronous BM who underwent first-line EGFR-tyrosine kinase inhibitor (TKI) Tx. The outcomes of patients were analyzed according to the clinicopathological characteristics including local Tx modalities. Results: Fifty-nine patients underwent local Tx for BM (gamma knife surgery [GKS], 37; whole brain radiotherapy [WBRT], 18; others, four) concurrently or sequentially with EGFR-TKI. Patients treated with TKI alone showed significantly lower incidence of central nervous system (CNS) symptoms. The median progression-free survival (PFS) and overall survival (OS) after the initiation of EGFR-TKI for all patients were 9 and 19 months, respectively. In 60 patients with follow-up brain imaging, the median time to CNS progression was 15 months. Patients with EGFR exon 19 deletion had a significantly longer median OS than those with other mutations including L858R (23 months vs. 17 months). Other clinical characteristics, including CNS symptoms, number of BM, and the use of local Tx were not associated with OS, as well as PFS. In terms of the local optimal Tx modality, no difference was found between GKS and WBRT in the OS and PFS. Conclusions: This study suggests that EGFR-TKI may result in a favorable outcome in NSCLC patients with synchronous BM, especially in deletion 19 mutant, regardless of the extent of BM lesions or local Tx modalities. Patients with asymptomatic BM can be treated with EGFR-TKI and careful surveillance.
Abstract
Background/Aims: The optimal treatment (Tx) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) remains to be determined. Methods: A retrospective review was conducted on 77 NSCLC patients with synchronous BM who underwent first-line EGFR-tyrosine kinase inhibitor (TKI) Tx. The outcomes of patients were analyzed according to the clinicopathological characteristics including local Tx modalities. Results: Fifty-nine patients underwent local Tx for BM (gamma knife surgery [GKS], 37; whole brain radiotherapy [WBRT], 18; others, four) concurrently or sequentially with EGFR-TKI. Patients treated with TKI alone showed significantly lower incidence of central nervous system (CNS) symptoms. The median progression-free survival (PFS) and overall survival (OS) after the initiation of EGFR-TKI for all patients were 9 and 19 months, respectively. In 60 patients with follow-up brain imaging, the median time to CNS progression was 15 months. Patients with EGFR exon 19 deletion had a significantly longer median OS than those with other mutations including L858R (23 months vs. 17 months). Other clinical characteristics, including CNS symptoms, number of BM, and the use of local Tx were not associated with OS, as well as PFS. In terms of the local optimal Tx modality, no difference was found between GKS and WBRT in the OS and PFS. Conclusions: This study suggests that EGFR-TKI may result in a favorable outcome in NSCLC patients with synchronous BM, especially in deletion 19 mutant, regardless of the extent of BM lesions or local Tx modalities. Patients with asymptomatic BM can be treated with EGFR-TKI and careful surveillance.
참고문헌 (26)
- Magnuson WJ, "Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer : a retrospective multi-institutional analysis", J Clin Oncol, 35, pp.1070~1077 (2017)
- Soon YY, "EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases : a systematic review and meta-analysis", Radiother Oncol, 114, pp.167~172 (2015)
- Ge M, "High probability and frequency of EGFR mutations in nonsmall cell lung cancer with brain metastases", J Neurooncol, 135, pp.413~418 (2017)
- Hsu F, "EGFR mutation status on brain metastases from non-small cell lung cancer", Lung Cancer, 96, pp.101~107 (2016)
- Saruwatari K, "Upfront cranial radiotherapy followed by erlotinib positively affects clinical outcomes of epidermal growth factor receptor-mutant non-small cell lung cancer with brain metastases", Anticancer Res, 39, pp.923~931 (2019)
- Chen H, "Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: a single institution retrospective analysis", Medicine(Baltimore), 97, pp.e13014~ (2018)
- Sung S, "Intracranial control and survival outcome of tyrosine kinase inhibitor(TKI)alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer", J Neurooncol, 139, pp.205~213 (2018)
- Liu S, "Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment : a retrospective clinical study", Radiat Oncol, 10, pp.118~ (2015)
- Choi YW, "EGFR exon 19 deletion is associated with favorable overall survival after first-line gefitinib therapy in advanced non-small cell lung cancer patients", Am J Clin Oncol, 41, pp.385~390 (2018)
- Park K, "Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer(LUX-Lung 7) : a phase 2B, open-label, randomized controlled trial", Lancet Oncol, 17, pp.577~589 (2016)
- Paz-Ares L, "Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-smallcell lung cancer : overall survival data from the phase IIb LUXLung 7 trial", Ann Oncol, 28, pp.270~277 (2017)
- Jiang H, "Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer", Mol Clin Oncol, 11, pp.301~308 (2019)
- Kim DW, "A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations", Lung Cancer, 71, pp.65~69 (2011)
- Iuchi T, "Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma", Lung Cancer, 82, pp.282~287 (2013)
- An N, "Therapeutic effect of first-line EGFR-TKIs combined with concurrent cranial radiotherapy on NSCLC patients with EGFR activating mutation and brain metastasis : a retrospective study", Onco Targets Ther, 12, pp.8311~8318 (2019)
- Chen Y, "Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis", BMC Cancer, 19, pp.793~ (2019)
- Chen Y, "First-line epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma", Cancer Sci, 107, pp.1800~1805 (2016)
- Ke SB, "Therapeutic effect of first-line epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)combined with whole brain radiotherapy on patients with EGFR mutation-positive lung adenocarcinoma and brain metastases", Curr Med Sci, 38, pp.1062~1068 (2018)
- Wang W, "Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis", Arch Med Sci, 14, pp.1298~1307 (2018)
- Zhu Q, "Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor(EGFR)mutant non small cell lung cancer(NSCLC)", Oncotarget, 8, pp.13304~13311 (2017)
- Du XJ, "Upfront cranial radiotherapy vs. EGFR tyrosine kinase inhibitors alone for the treatment of brain metastases from non-small-cell lung cancer : a meta-analysis of 1465 patients", Front Oncol, 8, pp.603~ (2018)
- Wang C, "Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation : a meta-analysis", Lung Cancer, 122, pp.94~99 (2018)
- Johung KL, "A clinical model for identifying radiosensitive tumor genotypes in non-small cell lung cancer", Clin Cancer Res, 19, pp.5523~5532 (2013)
- Chang EL, "Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation : a randomised controlled trial", Lancet Oncol, 10, pp.1037~1044 (2009)
- Habets EJ, "Neurocognitive functioning and health-related quality of life in patients treated with stereotactic radiotherapy for brain metastases : a prospective study", Neuro Oncol, 18, pp.435~444 (2016)
- Reungwetwattana T, "CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer", J Clin Oncol, 36, pp.3290~3297 (2018)